A Randomized, Blinded, Placebo-controlled Phase I Clinical Trial Evaluating the Safety and Preliminary Immunogenicity of a 11-valent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha) in Chinese Women Aged 9-45 Years

NCT04083196 · clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
90
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

National Vaccine and Serum Institute, China

Collaborators